|
Olaparib film-coated tablets is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2-negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.
With this approval the company can launch Olaparib film-coated tablets (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.
The pharmaceutical company posted a 2.6% rise in net profit to Rs 27.98 crore on a 10% increase in net sales to Rs 231.96 crore in Q4 FY22 over Q4 FY21.
Shares of AstraZeneca Pharma India rose 0.59% to currently trade at Rs 3,128.75 on the BSE.
|